{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:12:49Z","timestamp":1792897969257,"version":"4.5.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.autrev.2026.103993","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:16:49Z","timestamp":1770225409000},"page":"103993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment"],"prefix":"10.1016","volume":"25","author":[{"given":"Jelle","family":"Miedema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilario","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A.S.H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.103993_bb0005","article-title":"Sarcoidosis: a state-of-the-art review","author":"Miedema","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0010","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-0034-1376862","article-title":"Sarcoidosis and common variable immunodeficiency: similarities and differences","volume":"35","author":"Verbsky","year":"2014","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.autrev.2026.103993_bb0035","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.103993_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.autrev.2026.103993_bb0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MCP.0000000000000798","article-title":"Genetics in sarcoidosis","volume":"27","author":"Spagnolo","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0055","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1164\/ajrccm.164.11.2106001","article-title":"Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS)","volume":"164","author":"Rybicki","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0060","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1093\/hmg\/ddq325","article-title":"Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups","volume":"19","author":"Sato","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.autrev.2026.103993_bb0065","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/378097","article-title":"HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites","volume":"73","author":"Rossman","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.autrev.2026.103993_bb0070","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1164\/ajrccm.156.5.9704069","article-title":"HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis","volume":"156","author":"Berlin","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1164\/rccm.200807-1082OC","article-title":"Lofgren\u2019s syndrome: human leukocyte antigen strongly influences the disease course","volume":"179","author":"Grunewald","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0080","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1165\/rcmb.4782","article-title":"HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis","volume":"27","author":"Sato","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.autrev.2026.103993_bb0085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1519","article-title":"Sarcoidosis is associated with a truncating splice site mutation in BTNL2","volume":"37","author":"Valentonyte","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.autrev.2026.103993_bb0090","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ng.198","article-title":"Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis","volume":"40","author":"Hofmann","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.autrev.2026.103993_bb0095","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, immunologic, and environmental basis of sarcoidosis","volume":"14","author":"Moller","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.autrev.2026.103993_bb0100","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1164\/rccm.200803-490OC","article-title":"Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis","volume":"179","author":"Crouser","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1164\/rccm.200912-1855OC","article-title":"Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis","volume":"181","author":"Lockstone","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0110","article-title":"Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2026.103993_bb0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.201006-0865CI","article-title":"A concise review of pulmonary sarcoidosis","volume":"183","author":"Baughman","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.humimm.2018.05.007","article-title":"A sarcoidosis clinician's perspective of MHC functional elements outside the antigen binding site","volume":"80","author":"Judson","year":"2019","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0125","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1084\/jem.20040429","article-title":"Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis","volume":"201","author":"Song","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12016-015-8481-z","article-title":"Etiologies of sarcoidosis","volume":"49","author":"Chen","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/JCM.40.1.198-204.2002","article-title":"Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis","volume":"40","author":"Eishi","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.autrev.2026.103993_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-016-0332-z","article-title":"Is there any association between sarcoidosis and infectious agents?: a systematic review and meta-analysis","volume":"16","author":"Esteves","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.autrev.2026.103993_bb0145","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210785","article-title":"CD4+ T cells in the lungs of acute sarcoidosis patients recognize an aspergillus nidulans epitope","volume":"218","author":"Greaves","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MCP.0000000000000835","article-title":"Occupational exposures and sarcoidosis: current understanding and knowledge gaps","volume":"28","author":"Lin","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","author":"Miedema","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.autrev.2026.103993_bb0160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1183\/09031936.03.00083002","article-title":"Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis","volume":"21","author":"Fehrenbach","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0165","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03468-2020","article-title":"Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome","volume":"58","author":"Lepzien","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri3901","article-title":"Regulation of innate immune cell function by mTOR","volume":"15","author":"Weichhart","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3834","article-title":"The TSC-mTOR pathway regulates macrophage polarization","volume":"4","author":"Byles","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.autrev.2026.103993_bb0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1165\/rcmb.2018-0053OC","article-title":"IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model","volume":"60","author":"Locke","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.autrev.2026.103993_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106294","article-title":"High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis","volume":"177","author":"Pizzini","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0195","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4049\/jimmunol.166.1.642","article-title":"IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs","volume":"166","author":"Shigehara","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2249.2000.01365.x","article-title":"Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells","volume":"122","author":"Prasse","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0205","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01124-2017","article-title":"Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes","volume":"51","author":"Broos","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103120","article-title":"Circulating T cells in sarcoidosis have an aberrantly activated phenotype that correlates with disease outcome","author":"Miedema","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.autrev.2026.103993_bb0215","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201503-0635LE","article-title":"Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble?","volume":"192","author":"Broos","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-015-0265-8","article-title":"Impaired survival of regulatory T cells in pulmonary sarcoidosis","volume":"16","author":"Broos","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.autrev.2026.103993_bb0225","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.autrev.2026.103993_bb0230","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.immuni.2023.01.014","article-title":"Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation","volume":"56","author":"Krausgruber","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.103993_bb0235","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178711","article-title":"Recruitment of CXCR4+ type 1 innate lymphoid cells distinguishes sarcoidosis from other skin granulomatous diseases","volume":"134","author":"Sati","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.autrev.2026.103993_bb0240","article-title":"Single cell transcriptome signatures of sarcoidosis in lung immune cell populations","author":"Moore","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.autrev.2026.103993_bb0245","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02950-2020","article-title":"Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis","volume":"58","author":"Vukmirovic","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106161","article-title":"Current perspectives on the immunopathogenesis of sarcoidosis","volume":"173","author":"Lee","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0255","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00119-2019","article-title":"The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation","volume":"55","author":"Huppertz","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612792","article-title":"Simultaneous assessment of mTORC1, JAK\/STAT, and NLRP3 inflammasome activation pathways in patients with sarcoidosis","volume":"24","author":"Kraaijvanger","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.autrev.2026.103993_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170285","article-title":"Proteomic analysis of Kveim reagent identifies targets of cellular immunity in sarcoidosis","volume":"12","author":"Eberhardt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2026.103993_bb0270","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.yexcr.2007.03.040","article-title":"Novel functions of vimentin in cell adhesion, migration, and signaling","volume":"313","author":"Ivaska","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.autrev.2026.103993_bb0275","first-page":"125","article-title":"Cross-reactive and species specific mycobacterium tuberculosis antigens in the immunoprofile of Schaumann bodies: a major clue to the etiology of sarcoidosis","volume":"11","author":"Ang","year":"1996","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.autrev.2026.103993_bb0280","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02890384","article-title":"Immunofluorescence microscopic demonstration of vimentin filaments in asteroid bodies of sarcoidosis. A comparison with electron microscopic findings","volume":"42","author":"Cain","year":"1983","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"10.1016\/j.autrev.2026.103993_bb0285","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1172\/JCI32401","article-title":"Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis","volume":"117","author":"Wahlstrom","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.autrev.2026.103993_bb0290","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3389\/fimmu.2018.01516","article-title":"In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary sarcoidosis","volume":"9","author":"Kinloch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0295","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.25059","article-title":"Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis","volume":"62","author":"Feitsma","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2026.103993_bb0300","article-title":"Autoantibodies in sarcoidosis: innocent bystander or promising biomarker for organ involvement?","volume":"41","author":"Pozzan","year":"2024","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2026.103993_bb0305","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.autrev.2026.103993_bb0310","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.rmed.2013.01.004","article-title":"Concomitant sarcoidosis and a connective tissue disease: review of the clinical findings and postulations concerning their association","volume":"107","author":"Judson","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0315","article-title":"Autoimmune comorbidities associated with sarcoidosis: a case-control study in the all of us research program","volume":"7","author":"Murphy","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.autrev.2026.103993_bb0320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.46497\/ArchRheumatol.2020.7649","article-title":"Concomitant autoimmune diseases in patients with sarcoidosis in Turkey","volume":"35","author":"Yildiz","year":"2020","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.autrev.2026.103993_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103127","article-title":"Sarcoidosis and its relation to other immune-mediated diseases: epidemiological insights","volume":"149","author":"Arkema","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.autrev.2026.103993_bb0330","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1378\/chest.130.2.526","article-title":"Prevalence of hypothyroidism and graves disease in sarcoidosis","volume":"130","author":"Antonelli","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.103993_bb0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/pgmj.2008.067769","article-title":"Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database","volume":"85","author":"Rajoriya","year":"2009","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0340","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00385-2018","article-title":"Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study","volume":"52","author":"Rossides","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0345","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2024.05.014","article-title":"History and familial aggregation of immune-mediated diseases in sarcoidosis: a register-based case-control-family study","volume":"166","author":"Rossides","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.103993_bb0350","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2026.103993_bb0355","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12016-014-8450-y","article-title":"The clinical features of sarcoidosis: a comprehensive review","volume":"49","author":"Judson","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105998","article-title":"Clinical features and outcomes of asymptomatic pulmonary sarcoidosis. A comparative cohort study","volume":"169","author":"Iriarte","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0370","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rmed.2019.03.012","article-title":"Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis","volume":"152","author":"Judson","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0375","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2016.02.011","article-title":"The three tiers of screening for sarcoidosis organ involvement","volume":"113","author":"Judson","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0380","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccm.2015.08.010","article-title":"Cutaneous Sarcoidosis","volume":"36","author":"Wanat","year":"2015","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0385","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11916-011-0180-8","article-title":"Sarcoidosis and small-fiber neuropathy","volume":"15","author":"Tavee","year":"2011","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.autrev.2026.103993_bb0390","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-0030-1262216","article-title":"Quality of life in sarcoidosis: assessment and management","volume":"31","author":"De Vries","year":"2010","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0395","first-page":"33","article-title":"Impact of pain in a Dutch sarcoidosis patient population","volume":"20","author":"Hoitsma","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2026.103993_bb0400","first-page":"212","article-title":"Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment, respiration","volume":"80","author":"Elfferich","year":"2010","journal-title":"Int. Rev. Thoracic Dis."},{"key":"10.1016\/j.autrev.2026.103993_bb0405","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/jbmr.2262","article-title":"Calcium and vitamin D in sarcoidosis: is supplementation safe?","volume":"29","author":"Kamphuis","year":"2014","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.autrev.2026.103993_bb0410","first-page":"6","article-title":"How many organs need to be involved to diagnose sarcoidosis?: an unanswered question that, hopefully, will become irrelevant","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2026.103993_bb0415","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chest.2018.05.003","article-title":"Sarcoidosis diagnostic score: a systematic evaluation to enhance the diagnosis of sarcoidosis","volume":"154","author":"Bickett","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.103993_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00149","article-title":"Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis","volume":"11","author":"Ho","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606389","article-title":"What works when treating granulomatous disease in genetically undefined CVID? A systematic review","volume":"11","author":"van Stigt","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0430","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The European Society for Immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.autrev.2026.103993_bb0435","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.103993_bb0440","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2004.05.057","article-title":"Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency","volume":"114","author":"Bates","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0445","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10875-024-01817-3","article-title":"Granulomas in common variable immunodeficiency display different histopathological features compared to other granulomatous diseases","volume":"45","author":"van Stigt","year":"2024","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043588","article-title":"Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels","volume":"7","author":"Saussine","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2026.103993_bb0455","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00767-2020","article-title":"Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study","volume":"56","author":"Rossides","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12071503","article-title":"Sarcoidosis versus granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency: a comparative review","volume":"12","author":"Buso","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2026.103993_bb0465","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1183\/09031936.00189011","article-title":"Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis","volume":"41","author":"Bouvry","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0470","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1183\/09031936.00025212","article-title":"Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function","volume":"40","author":"Nunes","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627423","article-title":"Granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID): a Multicenter retrospective study of patients from Italian PID referral Centers","volume":"12","author":"Cinetto","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0480","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s10875-023-01552-1","article-title":"Common and uncommon CT findings in CVID-related GL-ILD: correlations with clinical parameters, therapeutic decisions and potential implications in the differential diagnosis","volume":"43","author":"Scarpa","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0485","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10875-012-9778-9","article-title":"Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients","volume":"33","author":"Boursiquot","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0490","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1513\/AnnalsATS.201511-728OC","article-title":"Clinical predictors of a diagnosis of common variable immunodeficiency-related granulomatous-lymphocytic interstitial lung disease","volume":"13","author":"Mannina","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.autrev.2026.103993_bb0495","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.anai.2017.01.004","article-title":"Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency","volume":"118","author":"Hartono","year":"2017","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0500","doi-asserted-by":"crossref","first-page":"1451813","DOI":"10.3389\/fimmu.2024.1451813","article-title":"Investigating pulmonary and non-infectious complications in common variable immunodeficiency disorders: a UK national multi-Centre study","volume":"15","author":"Bintalib","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0505","series-title":"ERS Monograph","article-title":"Hepatic and splenic involvement","author":"Hamzeh","year":"2022"},{"key":"10.1016\/j.autrev.2026.103993_bb0510","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clim.2009.05.001","article-title":"Granulomatous disease in common variable immunodeficiency","volume":"133","author":"Ardeniz","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.autrev.2026.103993_bb0515","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccm.2023.08.008","article-title":"Hematologic and oncologic aspects of sarcoidosis: some of the least studied but most common dilemmas","volume":"45","author":"Lower","year":"2024","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0520","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/resp.14202","article-title":"Sarcoidosis-related mortality and the impact of corticosteroid treatment: a population-based cohort study","volume":"27","author":"Sikjaer","year":"2022","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2026.103993_bb0525","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccm.2023.09.002","article-title":"Biomarkers in sarcoidosis: beginning of a new era?","volume":"45","author":"van der Mark","year":"2024","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0530","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071607","article-title":"Risk indicators of sarcoidosis evolution-unified protocol (RISE-UP): protocol for a multi-Centre, longitudinal, observational study to identify clinical features that are predictive of sarcoidosis progression","volume":"13","author":"Drake","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2026.103993_bb0535","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCP.0000000000000604","article-title":"Indications for treatment of sarcoidosis","volume":"25","author":"Nunes","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0540","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: a world Association of Sarcoidosis and Other Granulomatous Disorders position paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","author":"Wells","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0545","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS clinical statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2026.103993_bb0550","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0555","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01629-2023","article-title":"In sarcoidosis trials, time also matters","volume":"63","author":"Jeny","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0560","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0565","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0570","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0575","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12948-015-0025-9","article-title":"Rituximab in refractory sarcoidosis: a single centre experience","volume":"13","author":"Cinetto","year":"2015","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.autrev.2026.103993_bb0580","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial","volume":"6","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.103993_bb0585","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03358-2020","article-title":"Lung transplantation for sarcoidosis: outcome and prognostic factors","volume":"58","author":"Le Pavec","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0590","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccm.2023.08.009","article-title":"Health-related quality of life assessment in sarcoidosis","volume":"45","author":"Judson","year":"2024","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0595","first-page":"147","article-title":"Pulmonary and psychosocial findings at enrollment in the ACCESS study","volume":"22","author":"Yeager","year":"2005","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2026.103993_bb0600","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2026.103993_bb0605","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-reported outcomes to support medical product labeling claims: FDA perspective","volume":"10","author":"Patrick","year":"2007","journal-title":"Value Health J. Int. Soc. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.autrev.2026.103993_bb0610","doi-asserted-by":"crossref","DOI":"10.2196\/38331","article-title":"Quality of life and physical activity in 629 individuals with sarcoidosis: prospective, cross-sectional study using smartphones (sarcoidosis app)","volume":"10","author":"Chu","year":"2022","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.autrev.2026.103993_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107483","article-title":"Cough monitoring for pulmonary sarcoidosis","volume":"221","author":"Judson","year":"2024","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0620","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1513\/AnnalsATS.201303-069FR","article-title":"Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes","volume":"10","author":"Patterson","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.autrev.2026.103993_bb0625","first-page":"154","article-title":"Predicting respiratory failure in sarcoidosis patients","volume":"14","author":"Baughman","year":"1997","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2026.103993_bb0630","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: comparison of survival with the general population and causes of death","volume":"38","author":"Nardi","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0635","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis","volume":"107","author":"Mostard","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0640","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PAS.0b013e3182785a2d","article-title":"End-stage sarcoid lung disease is distinct from usual interstitial pneumonia","volume":"37","author":"Xu","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.autrev.2026.103993_bb0645","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.103993_bb0650","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.129.6.1584","article-title":"Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis","volume":"129","author":"Kruit","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.103993_bb0655","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00330-013-3088-3","article-title":"Imaging aspects of the diagnosis of sarcoidosis","volume":"24","author":"Spagnolo","year":"2014","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.autrev.2026.103993_bb0660","article-title":"Prevalence of sarcoidosis-associated pulmonary hypertension: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0665","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.05.00083404","article-title":"Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics","volume":"25","author":"Shorr","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0670","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.103993_bb0675","article-title":"Sarcoidosis associated pulmonary hypertension","volume":"12","author":"Liu","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2026.103993_bb0680","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0165-2021","article-title":"WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension","volume":"31","author":"Savale","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.autrev.2026.103993_bb0685","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0690","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/09031936.00226911","article-title":"Global burden of chronic pulmonary aspergillosis complicating sarcoidosis","volume":"41","author":"Denning","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0695","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02396-2016","article-title":"Chronic pulmonary aspergillosis complicating sarcoidosis","volume":"49","author":"Uzunhan","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2026.103993_bb0700","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0000000000000906","article-title":"Hit-hard and early versus step-up treatment in severe sarcoidosis","volume":"28","author":"Vorselaars","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.autrev.2026.103993_bb0705","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/rheumatology\/kead373","article-title":"A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis","volume":"63","author":"Baker","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.103993_bb0710","author":"Roivant"},{"key":"10.1016\/j.autrev.2026.103993_bb0715","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.2147\/JIR.S378357","article-title":"Pharmacological inhibition of chitotriosidase (CHIT1) as a novel therapeutic approach for sarcoidosis","volume":"15","author":"Dymek","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.autrev.2026.103993_bb0720","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","volume":"163","author":"Culver","year":"2023","journal-title":"Chest"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:14:02Z","timestamp":1788174842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":144,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1568997226000078"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.103993","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.103993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103993"}}